Venclyxto Gets EU Nod – But Won't Be A Humira Replacement For AbbVie Yet
AbbVie and Genentech's chronic lymphocytic leukemia (CLL) drug Venclyxto has been recommended for conditional approval in Europe, but its initial limited patient population and potential reimbursement troubles won't see it replace top-seller Humira as a growth driver for AbbVie.
You may also be interested in...
Top-line MURANO data support Venclexta's current conditional approvals and expand its use into a broader population that should radically boost sales.
Label-expansion plans for Imbruvica, along with approvals for Venclexta and Rova-T headline AbbVie's efforts to build a substantial cancer portfolio. The BTK inhibitor was AbbVie's second-best seller in 2016, passing HCV combo Viekira Pak.
New data position BCL-2 inhibitor Venclexta, partnered with Roche, for roles in multiple myeloma and acute myeloid leukemia, among other indications beyond chronic lymphocytic leukemia.